News
Wockardt's US generics business has been loss-making for several years. In the financial year 2025, US generics posted a loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback